KP1077 Demonstrates Safety in Idiopathic Hypersomnia Patient

The phase 2 trial explored the safety and efficacy of KP1077 in reducing daytime sleepiness and sleep inertia.

Related Keywords

, Christopher Drake , Zevra Therapeutics Inc , Zevra Therapeutics , Epworth Sleepiness Scale , Therapeutics Inc , Adrian Quartel , Sleep Inertia Visual Analog Scale , Trial Highlights , Brain Fog Scale , Excessive Daytime Sleepiness ,